Comparative Pharmacology
Head-to-head clinical analysis: CONRAY versus OMNIPAQUE 350.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONRAY versus OMNIPAQUE 350.
CONRAY vs OMNIPAQUE 350
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Iothalamate meglumine is an ionic, high-osmolality radiopaque contrast agent that attenuates X-rays, allowing visualization of vascular structures and organs during radiographic procedures.
Radiopaque agent: iodine-containing contrast medium that attenuates X-rays, enhancing vascular and tissue contrast during imaging. Non-ionic, low-osmolar agent.
Intravenous: 20-60 mL for CT enhancement; intra-arterial: 5-80 mL per injection; concentration 282 mgI/mL (iothalamate meglumine). Dose based on procedure, body weight, and renal function.
1-2 mL/kg IV up to 150 mL for CT; 30-50 mL IV for DSA; max 350 mL per procedure.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours in patients with normal renal function; prolonged in renal impairment.
Terminal elimination half-life is approximately 1.5–2 hours in patients with normal renal function. May be prolonged in renal impairment.
Primarily renal excretion via glomerular filtration; >90% of administered dose eliminated unchanged in urine within 24 hours. Less than 1% biliary or fecal.
Primarily renal excretion via glomerular filtration; >95% eliminated unchanged in urine within 24 hours. Biliary/fecal excretion is negligible (<1%).
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent